Sosnowska-Sienkiewicz Patrycja, Moryciński Sebastian, Januszkiewicz-Lewandowska Danuta, Michalik Karolina, Madziar Klaudyna, Kukfisz Agata, Zielińska Daria, Mańkowski Przemysław
Department of Pediatric Surgery, Traumatology and Urology, Poznan University of Medical Sciences, Poznan, Poland.
Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Front Oncol. 2024 Apr 16;14:1351630. doi: 10.3389/fonc.2024.1351630. eCollection 2024.
Totally Implantable Venous Access Devices (TIVADs) contribute significantly to the treatment progress and comfort of patients requiring long-term therapy. However, the procedure for implanting TIVADs, as well as its very presence, may be associated with complications.
This study evaluates the indications, safety, and complication rates of venous port implantations in pediatric patients. It also explores factors influencing the occurrence of early and late complications post-implantation.
The study included 383 pediatric patients treated at the Department of Pediatric Surgery, Traumatology, and Urology in Poznan between 2013 and 2020 who underwent 474 implantations of intravenous ports. Venous access was achieved using the Seldinger technique. Statistical analysis was performed using Statistica 13 with TIBCO and PQStat 1.8.2.156 with PQStat.
Venous ports were used in 345 oncology patients requiring chemotherapy (90% of the total group) and in 38 children (10%) with non-oncology indications. There were 36 early complications (7.6%) and 18 late complications (3.8%), excluding infectious complications. The most common early, non-infectious complications included pneumothorax (15 patients; 3%) and port pocket hematoma (12 patients; 2.5%). The most common late, non-infectious complications observed were venous catheter obstruction (8 children; 1.7%) and port system leakage (5 children; 1%). Infectious complications occurred in 129 cases (27.2%). Children with a diagnosis of non-Hodgkin's lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia had a significantly higher incidence of port infections. Venous ports equipped with a polyurethane catheter, compared to systems with a silicone catheter, functioned significantly shorter.
The Seldinger method of port implantation is quick, minimally invasive, and safe. The type of port, including the material of the port's venous catheter, and the underlying disease have an impact on the durability of implantable intravenous systems. The experience of the surgeon is related to the frequency of complications associated with the procedure.
完全植入式静脉通路装置(TIVADs)对需要长期治疗的患者的治疗进展和舒适度有显著贡献。然而,TIVADs的植入过程及其存在本身可能会引发并发症。
本研究评估儿科患者静脉端口植入的适应症、安全性和并发症发生率。还探讨了影响植入后早期和晚期并发症发生的因素。
该研究纳入了2013年至2020年期间在波兹南儿科外科、创伤学和泌尿外科接受治疗的383名儿科患者,他们接受了474次静脉端口植入。采用Seldinger技术建立静脉通路。使用TIBCO的Statistica 13和PQStat的PQStat 1.8.2.156进行统计分析。
345名需要化疗的肿瘤患者(占总组的90%)和38名有非肿瘤适应症的儿童(占10%)使用了静脉端口。排除感染性并发症后,有36例早期并发症(7.6%)和18例晚期并发症(3.8%)。最常见的早期非感染性并发症包括气胸(15例患者;3%)和端口袋血肿(12例患者;2.5%)。观察到的最常见的晚期非感染性并发症是静脉导管阻塞(8名儿童;1.7%)和端口系统渗漏(5名儿童;1%)。感染性并发症发生129例(27.2%)。诊断为非霍奇金淋巴瘤、急性髓系白血病和急性淋巴细胞白血病的儿童端口感染发生率显著更高。与配备硅胶导管的系统相比,配备聚氨酯导管的静脉端口功能明显更短。
Seldinger法端口植入快速、微创且安全。端口类型,包括端口静脉导管的材料,以及基础疾病,对可植入静脉系统的耐用性有影响。外科医生的经验与该手术相关并发症的发生率有关。